Table 4. Morbidity and mortality rates of cytoreductive surgery and HIPEC in selected new centers and early reports of established centers.
| Authors | Center | Morbidity (%) | Mortality (%) |
|---|---|---|---|
| Selected new peritoneal surface malignancy centers (after 2005) | |||
| Tabrizian et al. (29) | Mount Sinai Medical Center, NY, USA | 52.4a | 2.4 |
| Kerscher et al. (30) | University Hospital of Wurzburg, Germany | 30.2b | 0 |
| Konstantinidis et al. (31) | University of Arizona, USA | 36.0a | 0 |
| Arias et al. (32) | Fundación Santa Fe de Bogotá, Colombia | 37.5c | 2.8 |
| Garcia-Matus et al. (33) | HRAEO, Mexico | 19.5a | 3.8 |
| Turrini et al. (34) | Institut Paoli-Calmettes, France | 33.0a | 0 |
| Mizumoto et al. (10) | Kusatsu General Hospital, Japan | 45.0a | 3.5 |
| Selected established peritoneal surface malignancy centers (before 2005) | |||
| Gusani et al. (35) | University of Pittsburgh Medical Center, USA | 56.5a | 1.6 |
| Kuijpers et al. (36) | Netherlands Cancer Institute, Amsterdam | 64.0b,d | 13.0d |
| Levine et al. (37) | Wake Forest University, USA | 43.1a | 4.3 |
| Stephens et al. (8) | Washington Cancer Institute, USA | 27.0b | 1.5 |
| Piso et al. (38) | University of Regensburg, Germany | 34.0a | 4.5 |
| Glehen et al. (9) | Centre Hospitalo-Universitaire Lyon Sud, France | 24.5b | 3.2 |
| Van Leeuwen et al. (16) | Uppsala University Hospital, Sweden | 56.3a | 0.9 |
a, Overall morbidity rate; b, grade III/IV morbidity rate; c, major safety events rate; d, rates from pre-2005 pioneer phase of study. HIPEC, hyperthermic intra-peritoneal chemoperfusion; HRAEO, Hospital Regional de Alta Especialidad de Oaxaca.